Seminars in thrombosis and hemostasis最新文献_第8页

Dosing Intensity of Anticoagulants for the Prevention and Treatment of Venous Thromboembolism and the Prevention of Stroke in Atrial Fibrillation: Why is There a Difference? 预防和治疗静脉血栓栓塞和预防心房颤动中风的抗凝剂剂量强度：为何存在差异？

IF 5.7 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-06-18 DOI: 10.1055/s-0044-1787726

Jack Hirsh, Alejandro Godoy, Noel C Chan

引用次数: 0

Platelet Pathophysiology: Unexpected New Research Directions. 血小板病理生理学：意想不到的新研究方向

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-06-18 DOI: 10.1055/s-0044-1787663

Alan D Michelson, Andrew L Frelinger Iii, Robin L Haynes, Hannah C Kinney, Thomas Gremmel

引用次数: 0

Laboratory Testing for Fibrinogen Disorders: From Routine Investigations to Research Studies. 纤维蛋白原紊乱的实验室检测：从常规检查到研究调查。

IF 5.7 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-06-18 DOI: 10.1055/s-0044-1787725

Anetta Undas

{"title":"Laboratory Testing for Fibrinogen Disorders: From Routine Investigations to Research Studies.","authors":"Anetta Undas","doi":"10.1055/s-0044-1787725","DOIUrl":"https://doi.org/10.1055/s-0044-1787725","url":null,"abstract":"Congenital and acquired fibrinogen disorders often have heterogeneous clinical phenotypes and are challenging from a laboratory perspective. Fibrinogen determination using the Clauss method remains the gold standard, while the reproducibility and significance of the thrombin time and the reptilase time are limited. Molecular testing for causative mutations in fibrinogen genes is now recommended to confirm the diagnosis of congenital fibrinogen disorders. Research assays are used to evaluate alterations to fibrin formation and properties of plasma and purified fibrinogen-derived clots, characterized by fiber thickness, the number of branches, and pore sizes. Fibrin clot permeability (permeation, porosity) using a hydrostatic pressure system represents the most commonly used method for evaluating fibrin network density. Reduced clot permeability, which denotes the reduced size of an average pore in the network, results in tighter fibrin networks, typically associated with impaired susceptibility to lysis, leading to a thrombotic tendency. Biophysical properties of fibrin clots are largely assessed using rheometry, with atomic force microscopy and nanorheology being increasingly used in disease states. Thromboelastography and thromboelastometry, a simple modification of rheometry, have been used, mainly in intensive care units, for more than 50 years. Given growing evidence for altered fibrin clot properties in diseases with elevated risk of venous and arterial thromboembolism and in some bleeding disorders, further work on standardization and validation of the assessment of fibrin clot characteristics is needed. This review summarizes the current methods used to evaluate fibrinogen abnormalities in both diagnostic and research laboratories.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141420732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents. 在使用埃米珠单抗或其他新型/新兴止血剂的情况下进行因子检测的策略。

IF 5.7 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-06-12 DOI: 10.1055/s-0044-1787189

Geoffrey Kershaw

{"title":"Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents.","authors":"Geoffrey Kershaw","doi":"10.1055/s-0044-1787189","DOIUrl":"https://doi.org/10.1055/s-0044-1787189","url":null,"abstract":"For several decades, therapeutic options for inherited deficiencies of factor VIII or IX (hemophilia A or B, respectively) have largely been the replacement of the missing clotting factor with plasma-derived or recombinant products. Hemostasis laboratories use standard activated partial thromboplastin time (aPTT)-based clotting or chromogenic assays to monitor plasma factor levels to guide therapy. The emergence in the past 10 years of extended half-life replacement products and other novel therapies for hemophilia has led to a reappraisal of assay suitability, with studies of product measurement showing some existing assay types or reagents to be unsuitable for some products. The hemostasis laboratory must adapt to the changing landscape by adding new assays or modifying existing assays to ensure accurate results for product measurement. These strategies include switching from a chromogenic assay to a clotting assay, or vice versa, changing an aPTT reagent brand, or introducing product specific calibrators. This article evaluates the effects of some of the newer treatment options on the laboratory testing of factor levels and related assays.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis and Treatment of Autoimmune Acquired Coagulation Factor Deficiencies: An Evidence-Based Review of Japanese Practice. 自身免疫性获得性凝血因子缺乏症的诊断与治疗：基于证据的日本实践回顾。

IF 5.7 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-06-12 DOI: 10.1055/s-0044-1787188

Akitada Ichinose, Tsukasa Osaki, Masayoshi Souri

{"title":"Diagnosis and Treatment of Autoimmune Acquired Coagulation Factor Deficiencies: An Evidence-Based Review of Japanese Practice.","authors":"Akitada Ichinose, Tsukasa Osaki, Masayoshi Souri","doi":"10.1055/s-0044-1787188","DOIUrl":"https://doi.org/10.1055/s-0044-1787188","url":null,"abstract":"Among the acquired coagulation factor deficiencies, autoimmune coagulation factor deficiencies (AiCFD) are rare and result from autoantibody production against coagulation factors. In Japan, a nationwide survey on AiCFD has been conducted since 2009. Autoimmune factor XIII, factor VIII, von Willebrand factor, factor V, and factor X deficiencies (AiF13D, AiF8D, AiVWFD, AiF5D, and AiF10D, respectively) have been enacted as \"designated intractable disease-282.\" The incidence of AiF8D, AiF13D, and AiF5D was 1.83, 0.044, and 0.038 per million people/year, respectively, whereas that of AiVWFD and AiF10D was not calculable owing to the small number of patients. AiF13D and AiF8D were often idiopathic, whereas AiVWFD was often associated with plasma cell neoplasms. Epistaxis was a characteristic symptom of AiVWFD, intramuscular bleeding was frequent in AiF13D and AiF8D, and subcutaneous bleeding (purpura) was frequent in AiF13D and AiF10D, although none were specific to any one disease. Differential diagnosis cannot be made based on bleeding symptoms alone; therefore, rapid and accurate testing is mandatory. Definitive diagnosis of AiCFD necessitates identifying the presence of coagulation factor \"inhibitors\" and/or \"autoantibodies.\" Therefore, these tests should be performed upon unexplained severe acquired coagulation factor deficiencies. The mainstay of treatment for AiCFD was hemostatic therapy and autoantibody eradication therapy, which included the replacement of coagulation factors or \"bypass\" agents and administration of immunosuppressants. The rate of hemorrhagic death was high in AiF13D (13%), followed by AiF5D (7%) and Ai10D (5%); therefore, early diagnosis and optimal treatment are essential for AiCFDs. Given the unknown long-term prognosis, \"intractable disease platform registries\" have begun to accumulate in Japan.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Perspective on How Fibrinaloid Microclots and Platelet Pathology May be Applied in Clinical Investigations. 纤维蛋白微切片和血小板病理学在临床研究中的应用前景。

IF 5.7 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-06-01 Epub Date: 2023-09-25 DOI: 10.1055/s-0043-1774796

Etheresia Pretorius, Douglas B Kell

{"title":"A Perspective on How Fibrinaloid Microclots and Platelet Pathology May be Applied in Clinical Investigations.","authors":"Etheresia Pretorius, Douglas B Kell","doi":"10.1055/s-0043-1774796","DOIUrl":"10.1055/s-0043-1774796","url":null,"abstract":"Microscopy imaging has enabled us to establish the presence of fibrin(ogen) amyloid (fibrinaloid) microclots in a range of chronic, inflammatory diseases. Microclots may also be induced by a variety of purified substances, often at very low concentrations. These molecules include bacterial inflammagens, serum amyloid A, and the S1 spike protein of severe acute respiratory syndrome coronavirus 2. Here, we explore which of the properties of these microclots might be used to contribute to differential clinical diagnoses and prognoses of the various diseases with which they may be associated. Such properties include distributions in their size and number before and after the addition of exogenous thrombin, their spectral properties, the diameter of the fibers of which they are made, their resistance to proteolysis by various proteases, their cross-seeding ability, and the concentration dependence of their ability to bind small molecules including fluorogenic amyloid stains. Measuring these microclot parameters, together with microscopy imaging itself, along with methodologies like proteomics and imaging flow cytometry, as well as more conventional assays such as those for cytokines, might open up the possibility of a much finer use of these microclot properties in generative methods for a future where personalized medicine will be standard procedures in all clotting pathology disease diagnoses.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11105946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41165242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of Platelets in Rheumatic Chronic Autoimmune Inflammatory Diseases. 血小板在风湿性慢性自身免疫性炎症疾病中的作用

IF 5.7 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-06-01 Epub Date: 2023-11-28 DOI: 10.1055/s-0043-1777071

Martin Jozef Péč, Jakub Jurica, Monika Péčová, Jakub Benko, Juraj Sokol, Tomáš Bolek, Marek Samec, Tatiana Hurtová, Peter Galajda, Matej Samoš, Marián Mokáň

引用次数: 0

A Novel Variant on the Thrombospondin Type-1 Repeat 2 Domain of ADAMTS13 in a Parturient with Suspected Hereditary Thrombotic Thrombocytopenic Purpura and Unusually High ADAMTS13 Activity. 一名疑似遗传性血栓性血小板减少性紫癜和异常高ADAMTS13活性的产妇中ADAMTS13的血小板反应蛋白1型重复序列2结构域的新变体。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-06-01 Epub Date: 2023-09-19 DOI: 10.1055/s-0043-1774382

Junkun Chen, Ning Tang, Xiong Wang, Jiaoyuan Li

引用次数: 0

What Role Does Microthrombosis Play in Long COVID? 微血栓形成在长期新冠肺炎中扮演什么角色？

IF 5.7 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-06-01 Epub Date: 2023-09-25 DOI: 10.1055/s-0043-1774795

Toshiaki Iba, Jean M Connors, Jerrold H Levy

{"title":"What Role Does Microthrombosis Play in Long COVID?","authors":"Toshiaki Iba, Jean M Connors, Jerrold H Levy","doi":"10.1055/s-0043-1774795","DOIUrl":"10.1055/s-0043-1774795","url":null,"abstract":"Soon after the outbreak of coronavirus disease 2019 (COVID-19), unexplained sustained fatigue, cognitive disturbance, and muscle ache/weakness were reported in patients who had recovered from acute COVID-19 infection. This abnormal condition has been recognized as \"long COVID (postacute sequelae of COVID-19 [PASC])\" with a prevalence estimated to be from 10 to 20% of convalescent patients. Although the pathophysiology of PASC has been studied, the exact mechanism remains obscure. Microclots in circulation can represent one of the possible causes of PASC. Although hypercoagulability and thrombosis are critical mechanisms of acute COVID-19, recent studies have reported that thromboinflammation continues in some patients, even after the virus has cleared. Viral spike proteins and RNA can be detected months after patients have recovered, findings that may be responsible for persistent thromboinflammation and the development of microclots. Despite this theory, long-term results of anticoagulation, antiplatelet therapy, and vascular endothelial protection are inconsistent, and could not always show beneficial treatment effects. In summary, PASC reflects a heterogeneous condition, and microclots cannot explain all the presenting symptoms. After clarification of the pathomechanisms of each symptom, a symptom- or biomarker-based stratified approach should be considered for future studies.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41165243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Whole Blood Viscosity and Cerebral Blood Flow in Acute Ischemic Stroke. 急性缺血性脑卒中的全血粘度和脑血流量。

IF 5.7 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-06-01 Epub Date: 2023-10-09 DOI: 10.1055/s-0043-1775858

Prajwal Gyawali, Thomas P Lillicrap, Carlos G Esperon, Aseem Bhattarai, Andrew Bivard, Neil Spratt

{"title":"Whole Blood Viscosity and Cerebral Blood Flow in Acute Ischemic Stroke.","authors":"Prajwal Gyawali, Thomas P Lillicrap, Carlos G Esperon, Aseem Bhattarai, Andrew Bivard, Neil Spratt","doi":"10.1055/s-0043-1775858","DOIUrl":"10.1055/s-0043-1775858","url":null,"abstract":"Existing effective treatments for ischemic stroke restore blood supply to the ischemic region using thrombolysis or mechanical removal of clot. However, it is increasingly recognized that successful removal of occlusive thrombus from the large artery-recanalization, may not always be accompanied by successful restoration of blood flow to the downstream tissues-reperfusion. Ultimately, brain tissue survival depends on cerebral perfusion, and a functioning microcirculation. Because capillary diameter is often equal to or smaller than an erythrocyte, microcirculation is largely dependent on erythrocyte rheological (hemorheological) factors such as whole blood viscosity (WBV). Several studies in the past have demonstrated elevated WBV in stroke compared with healthy controls. Also, elevated WBV has shown to be an independent risk factor for stroke. Elevated WBV leads to endothelial dysfunction, decreases nitric oxide-dependent flow-mediated vasodilation, and promotes hemostatic alterations/thrombosis, all leading to microcirculation sludging. Compromised microcirculation further leads to decreased cerebral perfusion. Hence, modulating WBV through pharmacological agents might be beneficial to improve cerebral perfusion in stroke. This review discusses the effect of elevated WBV on endothelial function, hemostatic alterations, and thrombosis leading to reduced cerebral perfusion in stroke.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41183547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0